Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Operating Expenses (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Operating Expenses for 6 consecutive years, with $67.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 20.42% to $67.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $318.1 million through Dec 2025, down 16.83% year-over-year, with the annual reading at $318.1 million for FY2025, 16.83% down from the prior year.
  • Operating Expenses for Q4 2025 was $67.6 million at Relay Therapeutics, down from $80.4 million in the prior quarter.
  • The five-year high for Operating Expenses was $194.4 million in Q2 2021, with the low at $43.4 million in Q1 2021.
  • Average Operating Expenses over 5 years is $88.4 million, with a median of $85.6 million recorded in 2022.
  • The sharpest move saw Operating Expenses skyrocketed 601.41% in 2021, then plummeted 59.79% in 2022.
  • Over 5 years, Operating Expenses stood at $68.3 million in 2021, then grew by 7.05% to $73.1 million in 2022, then rose by 26.11% to $92.2 million in 2023, then dropped by 7.83% to $85.0 million in 2024, then decreased by 20.42% to $67.6 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $67.6 million, $80.4 million, and $77.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.